基于α-氧酸的离子液体和的双重功能超分子系统,用于增强抗衰老的通过皮肤递送
Zhenyuan Wang1,2, Lu Zhang3, Biao Wang2
1Sauvage Laboratory for Smart Materials, School of Materials Science and Engineering, Harbin Institute of Technology (Shenzhen), Shenzhen 518055, China. wangmi@hit.edu.cn.
Journal of materials chemistry. B
|July 8, 2025
概括
这项研究引入了一种新型的抗衰老化系统,该系统结合了酸衍生离子液 (BMa) 和乙六-8 (AHP-8) 进行优异的透皮传递,通过增强原蛋白和抑制神经递质,有效减少纹.
科学领域:
- 化品科学 化品科学
- 材料科学 材料科学 材料科学
- 生物技术是生物技术.
背景情况:
- 老化皮肤表现出动态和静态的纹由于神经递质释放和减少原.
- 目前的抗衰老疗法往往缺乏足够的通过皮肤递送以获得最佳疗效.
- 乙六-8 (AHP-8) 是一种以抗纹特性而闻名的,但面临着交付挑战.
研究的目的:
- 开发一种双重功能的超分子联合组装系统,以增强抗衰老的通过皮肤递送.
- 研究酸衍生离子液 (BMa) 和AHP-8对减少纹的协同作用.
- 评估该系统在促进原蛋白生产和抑制神经递质释放方面的有效性.
主要方法:
- 使用 BMa 和 AHP-8 构建一个超分子联合组装系统.
- 在体外通过皮肤透的研究.
- 分子动力学模拟以阐明增强透的机制.
- 细胞测试以评估原I生产和乙胆释放.
- 一种BMa/AHP-8面部奶油的临床试验.
主要成果:
- 与自由AHP-8相比,BMa/AHP-8系统的AHP-8通过皮浸透率增加了3.10倍.
- 分子动力学模拟表明,BMa降低了AHP-8穿透皮肤的能量屏障.
- 细胞测试显示通过TGF-β通路调节和高级乙胆抑制增强了 I 原蛋白的产生.
- 临床试验证实,BMa/AHP-8奶油应用28天后,纹参数 (数量,长度,面积) 显著减少.
结论:
- BMa/AHP-8超分子系统提供了一种高效的方法,可以通过皮肤传递抗衰老药物.
- 这种双重功能系统通过联合机制解决动态和静态纹.
- 这些发现支持开发新的,非侵入性的化品配方,用于先进的皮肤再生.
相关概念视频
01:27Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
01:18Transdermal Drug Delivery Systems
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...